Can Adiponectin Help us to Target Diastolic Dysfunction?

• Type: Another Publication in an International Scientific Journal
• Date: 2016

Authors

Francisco, C (Author) Other; Neves, JS (Author) FMUP; Falcao Pires, I (Author) FMUP; Leite-Moreira AF (Author) FMUP

Journal

Title: Cardiovascular Drugs and Therapy

Vol. 30

Pages: 635-644

ISSN: 0920-3206

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 18 Citations

Scopus - 17 Citations

Other information

Authenticus ID: P-00M-4H6

DOI: 10.1007/s10557-016-6694-x

Abstract (EN): Adiponectin is the most abundant adipokine and exhibits anti-inflammatory, antiatherogenic and antidiabetic properties. Unlike other adipokines, it inversely correlates with body weight and obesity-linked cardiovascular complications. Diastolic dysfunction is the main mechanism responsible for approximately half of all heart failure cases, the so-called heart failure with preserved ejection fraction (HFpEF), but therapeutic strategies specifically directed towards these patients are still lacking. In the last years, a link between adiponectin and diastolic dysfunction has been suggested. There are several mechanisms through which adiponectin may prevent most of the pathophysiologic mechanisms underlying diastolic dysfunction and HFpEF, including the prevention of myocardial hypertrophy, cardiac fibrosis, nitrative and oxidative stress, atherosclerosis and inflammation, while promoting angiogenesis. Thus, understanding the mechanisms underlying adiponectin-mediated improvement of diastolic function has become an exciting field of research, making adiponectin a promising therapeutic target. In this review, we explore the relevance of adiponectin signaling for the prevention of diastolic dysfunction and identify prospective therapeutic targets aiming at the treatment of this clinical condition.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10